|
US7053070B2
(en)
*
|
2000-01-25 |
2006-05-30 |
Warner-Lambert Company |
Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors
|
|
JP2004505974A
(ja)
*
|
2000-08-04 |
2004-02-26 |
ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー |
２−（４−ピリジル）アミノ−６−ジアルキルオキシフェニルピリド〔２，３−ｄ〕ピリミジン−７−オン類の製造方法
|
|
ATE303385T1
(de)
*
|
2000-08-04 |
2005-09-15 |
Warner Lambert Co |
Verfahren zur herstellung von 2-(4-pyridyl)amino- 6-dialkylolxaphenyl-pyrido(2,3-d)pyrimidon-7-on derivaten
|
|
YU63703A
(sh)
*
|
2001-02-12 |
2006-05-25 |
F. Hoffmann-La Roche Ag. |
6-supstituisani pirido-pirimidini
|
|
NZ527741A
(en)
*
|
2001-02-26 |
2005-02-25 |
Tanabe Seiyaku Co |
Pyridopyrimidine or naphthyridine derivative
|
|
US20030100572A1
(en)
*
|
2001-06-21 |
2003-05-29 |
Ariad Pharmaceuticals,Inc. |
Novel pyridopyrimidones and uses thereof
|
|
US20050154046A1
(en)
*
|
2004-01-12 |
2005-07-14 |
Longgui Wang |
Methods of treating an inflammatory-related disease
|
|
PL218692B1
(pl)
|
2002-01-22 |
2015-01-30 |
Warner Lambert Co |
Podstawiony 2-(pirydyn-2-yloamino)pirydo[2,3-d]pirymidyn-7-on oraz jego zastosowanie do leczenia zaburzenia lub stanu spowodowanego nieprawidłową proliferacją komórek
|
|
JP4252534B2
(ja)
|
2002-08-06 |
2009-04-08 |
エフ．ホフマン−ラ ロシュ アーゲー |
ｐ−３８ＭＡＰキナーゼインヒビターとしての６−アルコキシ−ピリド−ピリミジン類
|
|
US7129351B2
(en)
|
2002-11-04 |
2006-10-31 |
Hoffmann-La Roche Inc. |
Pyrimido compounds having antiproliferative activity
|
|
JP4666256B2
(ja)
|
2002-12-10 |
2011-04-06 |
小野薬品工業株式会社 |
含窒素複素環化合物およびその医薬用途
|
|
KR20050111636A
(ko)
|
2003-04-10 |
2005-11-25 |
에프. 호프만-라 로슈 아게 |
피리미도 화합물
|
|
AU2004255934B2
(en)
*
|
2003-07-11 |
2010-02-25 |
Warner-Lambert Company Llc |
Isethionate salt of a selective CDK4 inhibitor
|
|
NZ544756A
(en)
|
2003-07-22 |
2009-09-25 |
Astex Therapeutics Ltd |
3,4-Disubstituted 1H-pyrazole compounds and their use as cyclin dependent kinases (CDK) and glycogen synthase kinase-3 (GSK-3) modulators
|
|
KR20060036105A
(ko)
|
2003-07-29 |
2006-04-27 |
제논 파마슈티칼스 인크. |
피리딜 유도체 및 그의 치료제로서의 용도
|
|
EP1685131B1
(en)
*
|
2003-11-13 |
2007-03-07 |
F. Hoffmann-La Roche AG |
Hydroxyalkyl substituted pyrido-7-pyrimidin-7-ones
|
|
WO2005058341A2
(en)
*
|
2003-12-11 |
2005-06-30 |
Theravance, Inc. |
Compositions for use in the treatment of mutant receptor tyrosine kinase driven cellular proliferative diseases
|
|
DK1713806T3
(da)
*
|
2004-02-14 |
2013-08-05 |
Irm Llc |
Forbindelser og sammensætninger som proteinkinaseinhibitorer
|
|
EP1718645A1
(en)
*
|
2004-02-18 |
2006-11-08 |
Warner-Lambert Company LLC |
2-(pyridin-3-ylamino)-pyrido 2,3-d pyrimidin-7-ones
|
|
CA2561516A1
(en)
*
|
2004-03-30 |
2005-10-13 |
Pfizer Products Inc. |
Combinations of signal transduction inhibitors
|
|
PL1761528T3
(pl)
*
|
2004-06-11 |
2008-05-30 |
Japan Tobacco Inc |
Pochodne 5-amino-2,4,7-triokso-3,4,7,8-tetrahydro-2H-pirydo[2,3-D]pirymidyny i związki pokrewne do leczenia raka
|
|
US7378423B2
(en)
|
2004-06-11 |
2008-05-27 |
Japan Tobacco Inc. |
Pyrimidine compound and medical use thereof
|
|
US8003617B2
(en)
|
2004-11-10 |
2011-08-23 |
Genzyme Corporation |
Methods of treating diabetes mellitus
|
|
US20060142312A1
(en)
*
|
2004-12-23 |
2006-06-29 |
Pfizer Inc |
C6-aryl and heteroaryl substituted pyrido[2,3-D] pyrimidin-7-ones
|
|
CN101146532B
(zh)
*
|
2005-01-21 |
2012-05-09 |
阿斯泰克斯治疗有限公司 |
药物化合物
|
|
JP5475235B2
(ja)
*
|
2005-01-21 |
2014-04-16 |
アステックス・セラピューティクス・リミテッド |
医薬化合物
|
|
MX2007008809A
(es)
*
|
2005-01-21 |
2007-09-07 |
Astex Therapeutics Ltd |
Combinaciones de inhibidores de pirazol cinasa y otros agentes antitumor.
|
|
AR054425A1
(es)
|
2005-01-21 |
2007-06-27 |
Astex Therapeutics Ltd |
Sales de adicion de piperidin 4-il- amida de acido 4-(2,6-dicloro-benzoilamino) 1h-pirazol-3-carboxilico.
|
|
US8404718B2
(en)
|
2005-01-21 |
2013-03-26 |
Astex Therapeutics Limited |
Combinations of pyrazole kinase inhibitors
|
|
EP1852432A4
(en)
*
|
2005-02-25 |
2010-04-14 |
Ono Pharmaceutical Co |
NITROGENIC HETEROCYCLIC COMPOUND AND THEIR MEDICAL USE
|
|
PE20061351A1
(es)
*
|
2005-03-25 |
2007-01-14 |
Glaxo Group Ltd |
COMPUESTOS 8H-PIRIDO[2,3-d]PIRIMIDIN-7-ONA 2,4,8-TRISUSTITUIDOS COMO INHIBIDORES DE LA QUINASA CSBP/RK/p38
|
|
UY29439A1
(es)
*
|
2005-03-25 |
2006-10-02 |
Glaxo Group Ltd |
Nuevos compuestos
|
|
BR122020016659B8
(pt)
|
2005-05-10 |
2021-07-27 |
Incyte Holdings Corp |
moduladores de 2,3-dioxigenase de indolamina e métodos de modulação de atividade de inibição e de imunossupressão
|
|
KR100734837B1
(ko)
*
|
2005-09-16 |
2007-07-03 |
한국전자통신연구원 |
다중 생체 인식 시스템 및 그 방법
|
|
WO2007036791A1
(en)
*
|
2005-09-28 |
2007-04-05 |
Ranbaxy Laboratories Limited |
Pyrido-pyridimidine derivatives useful as antiinflammatory agents
|
|
JP5480503B2
(ja)
*
|
2005-10-07 |
2014-04-23 |
エクセリクシス， インク． |
ＰＩ３Ｋαのピリドピリミジノン型阻害剤
|
|
HRP20130902T1
(hr)
*
|
2005-10-07 |
2013-11-08 |
Exelixis Inc. |
PIRIDOPIRIMIDINONSKI INHIBITORI PI3Kalfa
|
|
JP2009536186A
(ja)
*
|
2006-05-08 |
2009-10-08 |
アステックス・セラピューティクス・リミテッド |
癌処置のためのジアゾール誘導体の医薬組合せ
|
|
WO2007134086A2
(en)
|
2006-05-09 |
2007-11-22 |
Genzyme Corporation |
Methods of treating fatty liver disease comprising inhibiting glucosphingolipid synthesis
|
|
EP2069344A2
(en)
*
|
2006-09-08 |
2009-06-17 |
Pfizer Products Inc. |
Synthesis of 2-(pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-ones
|
|
HRP20110621T2
(hr)
|
2006-09-15 |
2013-12-06 |
Pfizer Products Inc. |
SPOJEVI PIRIDO[2,3-d]PIRIMIDINONA I NJIHOVA UPOTREBA KAO INHIBITORI PI3
|
|
WO2008150260A1
(en)
*
|
2007-06-06 |
2008-12-11 |
Gpc Biotech, Inc. |
8-oxy-2-aminopyrido (2, 3-d) pyrimidin-7-one derivatives as kinase inhibitors and anticancer agents
|
|
WO2008047307A1
(en)
*
|
2006-10-16 |
2008-04-24 |
Gpc Biotech Inc. |
Pyrido [2, 3-d] pyrimidines and their use as kinase inhibitors
|
|
EP1914234A1
(en)
|
2006-10-16 |
2008-04-23 |
GPC Biotech Inc. |
Pyrido[2,3-d]pyrimidines and their use as kinase inhibitors
|
|
JP2010509265A
(ja)
*
|
2006-11-09 |
2010-03-25 |
エフ．ホフマン−ラ ロシュ アーゲー |
キナーゼ阻害剤としての置換６−フェニル−ピリド［２，３−ｄ］ピリミジン−７−オン誘導体及びそれの使用方法
|
|
WO2008063888A2
(en)
|
2006-11-22 |
2008-05-29 |
Plexxikon, Inc. |
Compounds modulating c-fms and/or c-kit activity and uses therefor
|
|
BRPI0817864A2
(pt)
|
2007-10-05 |
2012-12-25 |
Genzyme Corp |
uso de um composto derivado de ceramida
|
|
MX2010006457A
(es)
|
2007-12-19 |
2010-07-05 |
Amgen Inc |
Compuestos fusionados de piridina, pirimidina y triazina como inhibidores de ciclo celular.
|
|
JP5530422B2
(ja)
|
2008-04-07 |
2014-06-25 |
アムジエン・インコーポレーテツド |
細胞周期阻害薬としてのｇｅｍ−二置換およびスピロ環式アミノピリジン／ピリミジン
|
|
EP2112150B1
(en)
|
2008-04-22 |
2013-10-16 |
Forma Therapeutics, Inc. |
Improved raf inhibitors
|
|
RS57132B1
(sr)
|
2008-07-08 |
2018-07-31 |
Incyte Holdings Corp |
1,2,5-oksadiazoli kao inhibitori indolamin 2,3-dioksigenaze
|
|
JP2011529500A
(ja)
|
2008-07-28 |
2011-12-08 |
ジェンザイム コーポレーション |
虚脱性糸球体症および他の糸球体疾患の処置のためのグルコシルセラミドシンターゼ阻害
|
|
BRPI0917791B1
(pt)
*
|
2008-08-22 |
2022-03-22 |
Novartis Ag |
Compostos de pirrolopirimidina como inibidores de cdk, bem como composição farmacêutica e combinação
|
|
EP2341911A4
(en)
*
|
2008-10-01 |
2012-10-24 |
Univ North Carolina |
HEMATOPOIETIC PROTECTION AGAINST CHEMOTHERAPEUTIC COMPOUNDS USING SELECTIVE INHIBITORS OF KINASES DEPENDENT ON CYCLINES 4/6
|
|
WO2010051127A2
(en)
|
2008-10-01 |
2010-05-06 |
The University Of North Carolina At Chapel Hill |
Hematopoietic protection against ionizing radiation using selective cyclin-dependent kinase 4/6 inhibitors
|
|
EP3078373A1
(en)
|
2008-10-03 |
2016-10-12 |
Genzyme Corporation |
2-acylaminopropanol-type glucosylceramide synthase inhibitor
|
|
JO2885B1
(en)
|
2008-12-22 |
2015-03-15 |
ايلي ليلي اند كومباني |
Protein kinase inhibitors
|
|
MY160737A
(en)
|
2009-04-03 |
2017-03-15 |
Hoffmann La Roche |
Propane-i-sulfonic acid {3- [5-(4-chloro-phenyl) -1h -pyrrolo [2, 3-b] pyridine-3-carbonyl] -2,4 difluoro-phenyl} - amide compositions and uses thereof
|
|
AU2010248886A1
(en)
|
2009-05-13 |
2011-12-01 |
The University Of North Carolina At Chapel Hill |
Cyclin dependent kinase inhibitors and methods of use
|
|
JPWO2011025006A1
(ja)
*
|
2009-08-31 |
2013-01-31 |
日本ケミファ株式会社 |
Ｇｐｒ１１９作動薬
|
|
CN102648200A
(zh)
*
|
2009-10-09 |
2012-08-22 |
亚弗克希斯公司 |
用于治疗cns病症的8-乙基-6-(芳基)吡啶并[2，3-d]嘧啶-7(8h)-酮
|
|
SG10201407129SA
(en)
|
2009-11-06 |
2014-12-30 |
Plexxikon Inc |
Compounds and methods for kinase modulation, and indications therefor
|
|
JP5797664B2
(ja)
*
|
2009-12-18 |
2015-10-21 |
テンプル・ユニバーシティ−オブ・ザ・コモンウェルス・システム・オブ・ハイアー・エデュケイションＴｅｍｐｌｅ Ｕｎｉｖｅｒｓｉｔｙ−Ｏｆ Ｔｈｅ Ｃｏｍｍｏｎｗｅａｌｔｈ Ｓｙｓｔｅｍ Ｏｆ Ｈｉｇｈｅｒ Ｅｄｕｃａｔｉｏｎ |
置換ピリド［２，３−ｄ］ピリミジン−７（８Ｈ）−オン及びそれらの治療用の使用
|
|
PH12012501361A1
(en)
|
2009-12-31 |
2012-10-22 |
Centro Nac De Investigaciones Oncologicas Cnio |
Tricyclic compounds for use as kinase inhibitors
|
|
MX2012011912A
(es)
*
|
2010-04-13 |
2012-11-16 |
Novartis Ag |
Combinacion que comprende un inhibidor de cinasa 4 dependiente de ciclina o cinasa dependiente de ciclia (cdk4/6) y un inhibidor de mtor para tratar cancer.
|
|
TWI619713B
(zh)
|
2010-04-21 |
2018-04-01 |
普雷辛肯公司 |
用於激酶調節的化合物和方法及其適應症
|
|
EP2580217A4
(en)
*
|
2010-06-10 |
2014-06-18 |
Afraxis Holdings Inc |
6- (ETHYNYL-) PYRIDO- [2,3-D-] PYRIMIDIN-7- (8H) -ONE FOR THE TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM
|
|
ES2986590T3
(es)
|
2010-06-14 |
2024-11-12 |
Scripps Research Inst |
Reprogramación de células hacia un nuevo destino
|
|
PT2600719E
(pt)
|
2010-08-05 |
2014-12-22 |
Univ Temple |
8 ¿ alquilo -2 - substituído 7 ¿ oxo ¿ 7,8 ¿ diidropirido [2,3 ¿ d] pirimidina ¿ 6 ¿ carbonitrilos e seus usos
|
|
US8691830B2
(en)
|
2010-10-25 |
2014-04-08 |
G1 Therapeutics, Inc. |
CDK inhibitors
|
|
ES2592515T3
(es)
|
2010-10-25 |
2016-11-30 |
G1 Therapeutics, Inc. |
Inhibidores de CDK
|
|
WO2012068381A2
(en)
|
2010-11-17 |
2012-05-24 |
The University Of North Carolina At Chapel Hill |
Protection of renal tissues from schema through inhibition of the proliferative kisses cdk4 and cdk6
|
|
WO2012088266A2
(en)
|
2010-12-22 |
2012-06-28 |
Incyte Corporation |
Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
|
|
WO2012098387A1
(en)
|
2011-01-18 |
2012-07-26 |
Centro Nacional De Investigaciones Oncológicas (Cnio) |
6, 7-ring-fused triazolo [4, 3 - b] pyridazine derivatives as pim inhibitors
|
|
CN103517710B
(zh)
|
2011-02-07 |
2017-05-31 |
普莱希科公司 |
用于激酶调节的化合物
|
|
CN103703000B
(zh)
*
|
2011-03-23 |
2015-11-25 |
安姆根有限公司 |
Cdk4/6和flt3的稠合三环双重抑制剂
|
|
WO2012166586A1
(en)
|
2011-05-27 |
2012-12-06 |
Temple University - Of The Commonwealth System Of Higher Education |
SUBSTITUTED 2-BENZYLIDENE-2H-BENZO[b][1,4]THIAZIN-3(4H)-ONES, DERIVATIVES THEREOF, AND THERAPEUTIC USES THEREOF
|
|
JP6431770B2
(ja)
*
|
2012-03-14 |
2018-11-28 |
ルピン・リミテッド |
Ｍｅｋインヒビターとしてのヘテロシクリル化合物
|
|
AU2013239816B2
(en)
|
2012-03-29 |
2017-08-24 |
G1 Therapeutics, Inc. |
Lactam kinase inhibitors
|
|
US9150570B2
(en)
|
2012-05-31 |
2015-10-06 |
Plexxikon Inc. |
Synthesis of heterocyclic compounds
|
|
UA125503C2
(uk)
|
2012-06-13 |
2022-04-13 |
Інсайт Холдинґс Корпорейшн |
Заміщені трициклічні сполуки як інгібітори fgfr
|
|
RU2679130C2
(ru)
|
2012-07-11 |
2019-02-06 |
Блюпринт Медсинс Корпорейшн |
Ингибиторы рецептора фактора роста фибробластов
|
|
CA3163776A1
(en)
|
2012-08-03 |
2014-02-06 |
Foundation Medicine, Inc. |
Human papilloma virus as predictor of cancer prognosis
|
|
US9388185B2
(en)
|
2012-08-10 |
2016-07-12 |
Incyte Holdings Corporation |
Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
|
|
EP3492472A1
(en)
|
2012-08-17 |
2019-06-05 |
Concert Pharmaceuticals Inc. |
Deuterated baricitinib with improved metabolic stability as jak1 and jak2 kinase inhibitor for treating e.g. rheumatoid arthritis
|
|
US9266892B2
(en)
|
2012-12-19 |
2016-02-23 |
Incyte Holdings Corporation |
Fused pyrazoles as FGFR inhibitors
|
|
US20150353542A1
(en)
|
2013-01-14 |
2015-12-10 |
Amgen Inc. |
Methods of using cell-cycle inhibitors to modulate one or more properties of a cell culture
|
|
EP3431475B1
(en)
*
|
2013-02-21 |
2021-04-07 |
Pfizer Inc |
Solid forms of a selective cdk4/6 inhibitor
|
|
RS59790B1
(sr)
|
2013-03-15 |
2020-02-28 |
G1 Therapeutics Inc |
Privremena zaštita normalnih ćelija tokom hemoterapije
|
|
HK1222766A1
(zh)
|
2013-03-15 |
2017-07-14 |
G1治疗公司 |
高效的抗赘生剂和抗增生剂
|
|
US20160024084A1
(en)
|
2013-03-15 |
2016-01-28 |
Concert Pharmaceuticals, Inc. |
Deuterated palbociclib
|
|
MY181497A
(en)
|
2013-04-19 |
2020-12-23 |
Incyte Holdings Corp |
Bicyclic heterocycles as fgfr inhibitors
|
|
WO2014183520A1
(zh)
*
|
2013-05-17 |
2014-11-20 |
上海恒瑞医药有限公司 |
吡啶并嘧啶类衍生物、其制备方法及其在医药上的应用
|
|
WO2014203129A1
(en)
|
2013-06-19 |
2014-12-24 |
Olema Pharmaceuticals, Inc. |
Combinations of benzopyran compounds, compositions and uses thereof
|
|
EP3060560A1
(en)
|
2013-10-25 |
2016-08-31 |
Blueprint Medicines Corporation |
Inhibitors of the fibroblast growth factor receptor
|
|
US11013743B2
(en)
*
|
2013-12-20 |
2021-05-25 |
Biomed Valley Discoveries, Inc. |
Cancer treatments using combinations of CDK and ERK inhibitors
|
|
US9949976B2
(en)
|
2013-12-31 |
2018-04-24 |
Xuanzhu Pharma Co., Ltd. |
Kinase inhibitor and use thereof
|
|
PL3091008T3
(pl)
|
2013-12-31 |
2018-12-31 |
Xuanzhu Pharma Co., Ltd. |
Inhibitor kinazy i jego zastosowanie
|
|
US9695165B2
(en)
|
2014-01-15 |
2017-07-04 |
Blueprint Medicines Corporation |
Inhibitors of the fibroblast growth factor receptor
|
|
US20150297606A1
(en)
|
2014-04-17 |
2015-10-22 |
G1 Therapeutics, Inc. |
Tricyclic Lactams for Use in the Protection of Hematopoietic Stem and Progenitor Cells Against Ionizing Radiation
|
|
WO2015181737A1
(en)
|
2014-05-28 |
2015-12-03 |
Piramal Enterprises Limited |
Pharmaceutical combination for the treatment of cancer
|
|
CA2954298A1
(en)
|
2014-07-24 |
2016-01-28 |
Beta Pharma, Inc. |
2-h-indazole derivatives as cyclin-dependent kinase (cdk) inhibitors and therapeutic uses thereof
|
|
EP3172214B1
(en)
|
2014-07-26 |
2020-05-13 |
Sunshine Lake Pharma Co., Ltd. |
2-amino-pyrido[2,3-d]pyrimidin-7(8h)-one derivatives as cdk inhibitors and uses thereof
|
|
WO2016016769A1
(en)
*
|
2014-07-31 |
2016-02-04 |
Sun Pharmaceutical Industries Limited |
A process for the preparation of palbociclib
|
|
TW201618773A
(zh)
*
|
2014-08-11 |
2016-06-01 |
艾森塔製藥公司 |
Ｂｔｋ抑制劑、ｐｉ３ｋ抑制劑、ｊａｋ－２抑制劑、及／或ｃｄｋ４／６抑制劑的治療組合物
|
|
EP3180007A1
(en)
*
|
2014-08-14 |
2017-06-21 |
Sun Pharmaceutical Industries Ltd |
Crystalline forms of palbociclib
|
|
WO2016040848A1
(en)
|
2014-09-12 |
2016-03-17 |
G1 Therapeutics, Inc. |
Treatment of rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors
|
|
WO2016040858A1
(en)
|
2014-09-12 |
2016-03-17 |
G1 Therapeutics, Inc. |
Combinations and dosing regimes to treat rb-positive tumors
|
|
CN105111201B
(zh)
*
|
2014-10-16 |
2017-01-11 |
上海页岩科技有限公司 |
5-甲基-2-(吡啶-2-基氨基)-8H-吡啶并[2,3-d]嘧啶-7-酮化合物
|
|
US10851105B2
(en)
|
2014-10-22 |
2020-12-01 |
Incyte Corporation |
Bicyclic heterocycles as FGFR4 inhibitors
|
|
CN105622638B
(zh)
*
|
2014-10-29 |
2018-10-02 |
广州必贝特医药技术有限公司 |
嘧啶或吡啶并吡啶酮类化合物及其制备方法和应用
|
|
WO2016066420A1
(en)
*
|
2014-10-29 |
2016-05-06 |
Sandoz Ag |
Crystalline forms of palbociclib monohydrochloride
|
|
CN105616418A
(zh)
*
|
2014-11-07 |
2016-06-01 |
江苏豪森药业集团有限公司 |
含有细胞周期蛋白抑制剂的药物制剂及其制备方法
|
|
ES2941897T3
(es)
|
2014-11-12 |
2023-05-26 |
Seagen Inc |
Compuestos que interaccionan con glicanos y procedimientos de uso
|
|
CN104496983B
(zh)
|
2014-11-26 |
2016-06-08 |
苏州明锐医药科技有限公司 |
一种帕博西尼的制备方法
|
|
CN104447743B
(zh)
|
2014-11-26 |
2016-03-02 |
苏州明锐医药科技有限公司 |
帕博西尼的制备方法
|
|
WO2016090257A1
(en)
*
|
2014-12-05 |
2016-06-09 |
Crystal Pharmatech Inc. |
Salts and crystalline forms of 6-acetyl-8-cyclopentyl-5-methyl-2((5-(piperazin-1-yl)pyridin-2-yl)amino)pyrido[2,3-d] pyrimidin-7(8h)-one (palbociclib)
|
|
WO2016092442A1
(en)
*
|
2014-12-08 |
2016-06-16 |
Sun Pharmaceutical Industries Limited |
Processes for the preparation of crystalline forms of palbociclib acetate
|
|
JP6581197B2
(ja)
|
2014-12-31 |
2019-09-25 |
深▲セン▼市薬欣生物科技有限公司Ｓｈｅｎｚｈｅｎ Ｐｈａｒｍａｃｉｎ Ｃｏ．， Ｌｔｄ． |
医薬組成物及びその製造方法
|
|
CN105732615B
(zh)
*
|
2014-12-31 |
2018-05-01 |
山东轩竹医药科技有限公司 |
Cdk激酶抑制剂
|
|
CN104610254B
(zh)
*
|
2015-01-26 |
2017-02-01 |
新发药业有限公司 |
一种帕博赛布的低成本制备方法
|
|
CZ201589A3
(cs)
|
2015-02-11 |
2016-08-24 |
Zentiva, K.S. |
Pevné formy soli Palbociclibu
|
|
TWI690533B
(zh)
|
2015-02-12 |
2020-04-11 |
南北兄弟藥業投資有限公司 |
Ｃｄｋ類小分子抑制劑的化合物及其用途
|
|
MA41551A
(fr)
|
2015-02-20 |
2017-12-26 |
Incyte Corp |
Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
|
|
US9580423B2
(en)
|
2015-02-20 |
2017-02-28 |
Incyte Corporation |
Bicyclic heterocycles as FGFR4 inhibitors
|
|
CR20170390A
(es)
|
2015-02-20 |
2017-10-23 |
Incyte Holdings Corp |
Heterociclos biciclicos como inhibidores de fgfr
|
|
AR104068A1
(es)
|
2015-03-26 |
2017-06-21 |
Hoffmann La Roche |
Combinaciones de un compuesto inhibidor de fosfoinosítido 3-cinasa y un compuesto inhibidor de cdk4/6 para el tratamiento del cáncer
|
|
WO2016156070A1
(en)
|
2015-04-02 |
2016-10-06 |
Sandoz Ag |
Modified particles of palbociclib
|
|
EP3078663A1
(en)
|
2015-04-09 |
2016-10-12 |
Sandoz Ag |
Modified particles of palbociclib
|
|
CN106795159B
(zh)
*
|
2015-04-22 |
2018-12-28 |
江苏恒瑞医药股份有限公司 |
一种周期素依赖性蛋白激酶抑制剂的结晶形式及其制备方法
|
|
TWI696617B
(zh)
*
|
2015-04-28 |
2020-06-21 |
大陸商上海復尚慧創醫藥研究有限公司 |
特定蛋白質激酶抑制劑
|
|
LT3305785T
(lt)
*
|
2015-05-29 |
2021-11-10 |
Teijin Pharma Limited |
Pirido[3,4-d]pirimidino dariniai ir jų farmaciniu požiūriu priimtinos druskos
|
|
RU2686840C1
(ru)
|
2015-06-04 |
2019-05-06 |
Пфайзер Инк. |
Твёрдые лекарственные формы палбоциклиба
|
|
CN104892604B
(zh)
*
|
2015-06-19 |
2016-08-24 |
北京康立生医药技术开发有限公司 |
一种cdk4抑制剂的合成方法
|
|
CN106699785A
(zh)
*
|
2015-07-13 |
2017-05-24 |
南开大学 |
作为CDK4/6抑制剂的2-(N-氧化吡啶-2基氨基)-吡啶并[2,3-d]嘧啶-7-酮类化合物
|
|
WO2017021111A1
(en)
*
|
2015-08-05 |
2017-02-09 |
Ratiopharm Gmbh |
New crystalline form and acetic acid adducts of palbociclib
|
|
CN105085517B
(zh)
*
|
2015-08-06 |
2016-11-23 |
天津华洛康生物科技有限公司 |
一种结晶型帕博西尼游离碱水合物及其制备方法
|
|
CN105130986B
(zh)
*
|
2015-09-30 |
2017-07-18 |
广州科擎新药开发有限公司 |
嘧啶或吡啶并吡啶酮类化合物及其应用
|
|
HU230962B1
(hu)
|
2015-10-28 |
2019-06-28 |
Egis Gyógyszergyár Zrt. |
Palbociclib sók
|
|
CN106632311B
(zh)
*
|
2015-11-02 |
2021-05-18 |
上海科胜药物研发有限公司 |
一种帕博西尼晶型a和晶型b的制备方法
|
|
AU2016353153B2
(en)
|
2015-11-12 |
2023-11-23 |
Seagen Inc. |
Glycan-interacting compounds and methods of use
|
|
CN105418603A
(zh)
*
|
2015-11-17 |
2016-03-23 |
重庆莱美药业股份有限公司 |
一种高纯度帕布昔利布及其反应中间体的制备方法
|
|
CN106810536A
(zh)
|
2015-11-30 |
2017-06-09 |
甘李药业股份有限公司 |
一种蛋白激酶抑制剂及其制备方法和医药用途
|
|
EP3386981B1
(en)
*
|
2015-12-13 |
2021-10-13 |
Hangzhou Innogate Pharma Co., Ltd. |
Heterocycles useful as anti-cancer agents
|
|
CN105418609B
(zh)
*
|
2015-12-31 |
2017-06-23 |
山东大学 |
4‑(1,2,3‑三氮唑取代苯胺基)‑吡啶骈嘧啶酮衍生物及其制备方法与应用
|
|
JP6663021B2
(ja)
*
|
2015-12-31 |
2020-03-11 |
シャンハイ ファーマシューティカルズ ホールディング カンパニー，リミティド |
窒素含有縮合複素環化合物、製造方法、中間体、組成物および使用
|
|
CN106967061A
(zh)
*
|
2016-01-13 |
2017-07-21 |
常州方楠医药技术有限公司 |
帕博西林的盐、晶型及其制备方法
|
|
WO2017130219A1
(en)
|
2016-01-25 |
2017-08-03 |
Mylan Laboratories Limited |
Amorphous solid dispersion of palbociclib
|
|
WO2017145054A1
(en)
|
2016-02-24 |
2017-08-31 |
Lupin Limited |
Modified particles of crystalline palbociclib free base and process for the preparation thereof
|
|
US11077110B2
(en)
|
2016-03-18 |
2021-08-03 |
Tufts Medical Center |
Compositions and methods for treating and preventing metabolic disorders
|
|
US10449195B2
(en)
|
2016-03-29 |
2019-10-22 |
Shenzhen Pharmacin Co., Ltd. |
Pharmaceutical formulation of palbociclib and a preparation method thereof
|
|
CN107266421B
(zh)
*
|
2016-04-08 |
2020-12-04 |
正大天晴药业集团股份有限公司 |
取代的苯并咪唑类衍生物
|
|
CN107286180B
(zh)
*
|
2016-04-11 |
2019-07-02 |
上海勋和医药科技有限公司 |
杂代吡啶并嘧啶酮衍生物作为cdk抑制剂及其应用
|
|
AU2017254708B2
(en)
*
|
2016-04-22 |
2021-09-16 |
Dana-Farber Cancer Institute, Inc. |
Degradation of cyclin-dependent kinase 4/6 (CDK4/6) by conjugation of CDK4/6 inhibitors with E3 ligase ligand and methods of use
|
|
CN106336411B
(zh)
*
|
2016-04-27 |
2018-03-06 |
上海医药集团股份有限公司 |
Cdk4/6抑制剂帕博西尼高纯度原料药的制备工艺及用途
|
|
CN105949189B
(zh)
*
|
2016-06-05 |
2017-09-22 |
童明琼 |
一种用于治疗乳腺癌的帕博西尼的制备方法
|
|
WO2018005860A1
(en)
|
2016-07-01 |
2018-01-04 |
G1 Therapeutics, Inc. |
Pyrimidine-based antiproliferative agents
|
|
WO2018005863A1
(en)
|
2016-07-01 |
2018-01-04 |
G1 Therapeutics, Inc. |
Pyrimidine-based compounds for the treatment of cancer
|
|
WO2018005533A1
(en)
|
2016-07-01 |
2018-01-04 |
G1 Therapeutics, Inc. |
Antiproliferative pyrimidine-based compounds
|
|
US10807978B2
(en)
|
2016-07-04 |
2020-10-20 |
Dr. Reddy's Laboratories Limited |
Process for preparation of palbociclib
|
|
EP3481825A1
(en)
|
2016-07-07 |
2019-05-15 |
Plantex Ltd. |
Solid state forms of palbociclib dimesylate
|
|
MA45920B1
(fr)
*
|
2016-08-15 |
2021-08-31 |
Pfizer |
Inhibiteurs de pyridopyrimidinone cdk2/4/6
|
|
US20190175598A1
(en)
|
2016-08-23 |
2019-06-13 |
Eisai R&D Management Co., Ltd. |
Combination therapies for the treatment of hepatocellular carcinoma
|
|
WO2018049233A1
(en)
|
2016-09-08 |
2018-03-15 |
Nicolas Stransky |
Inhibitors of the fibroblast growth factor receptor in combination with cyclin-dependent kinase inhibitors
|
|
WO2018065999A1
(en)
|
2016-10-07 |
2018-04-12 |
Mylan Laboratories Limited |
Novel polymorph of an intermediate for palbociclib synthesis
|
|
BR112019005526A2
(pt)
|
2016-10-20 |
2019-06-18 |
Pfizer |
agentes antiproliferativos para tratamento de pah
|
|
WO2018073574A1
(en)
|
2016-10-20 |
2018-04-26 |
Cipla Limited |
Polymorphic forms of palbociclib
|
|
CN106565707B
(zh)
*
|
2016-11-03 |
2019-01-04 |
杭州科巢生物科技有限公司 |
帕博西尼新合成方法
|
|
EP3538148A1
(en)
|
2016-11-08 |
2019-09-18 |
Dana-Farber Cancer Institute |
Compositions and methods of modulating anti-tumor immunity
|
|
US20190275049A1
(en)
|
2016-11-16 |
2019-09-12 |
Pfizer Inc. |
Combination of an EGFR T790M Inhibitor and a CDK Inhibitor for the Treatment of Non-Small Cell Lung Cancer
|
|
WO2018094143A1
(en)
|
2016-11-17 |
2018-05-24 |
Siamab Therapeutics, Inc. |
Glycan-interacting compounds and methods of use
|
|
TWI799399B
(zh)
|
2016-11-28 |
2023-04-21 |
日商帝人製藥股份有限公司 |
吡啶并〔３，４－ｄ〕嘧啶衍生物及其藥學上所容許之鹽
|
|
NZ752990A
(en)
|
2016-11-28 |
2025-08-29 |
Teijin Pharma Ltd |
Crystal of pyrido[3, 4-d]pyrimidine derivative or solvate thereof
|
|
IL267299B
(en)
|
2016-12-16 |
2022-09-01 |
Cstone Pharmaceuticals |
Cdk4/6 inhibitor
|
|
CA3048057A1
(en)
|
2017-01-06 |
2018-07-12 |
G1 Therapeutics, Inc. |
Combination therapy for the treatment of cancer
|
|
CN108191857B
(zh)
*
|
2017-01-24 |
2020-10-23 |
晟科药业（江苏）有限公司 |
6-取代的吡啶并[2,3-d]嘧啶类化合物作为蛋白激酶抑制剂
|
|
US10729692B2
(en)
|
2017-02-26 |
2020-08-04 |
Institute For Cancer Research |
Dual inhibition of CDK and HSP90 destabilize HIF1alpha and synergistically induces cancer cell death
|
|
SG11201907889YA
(en)
|
2017-03-03 |
2019-09-27 |
Seattle Genetics Inc |
Glycan-interacting compounds and methods of use
|
|
US11192890B2
(en)
*
|
2017-03-03 |
2021-12-07 |
Auckland Uniservices Limited |
FGFR kinase inhibitors and pharmaceutical uses
|
|
US11083722B2
(en)
|
2017-03-16 |
2021-08-10 |
Eisai R&D Management Co., Ltd. |
Combination therapies for the treatment of breast cancer
|
|
CN108658854A
(zh)
*
|
2017-03-28 |
2018-10-16 |
中国海洋大学 |
一种生物碱化合物及其制备方法和作为海洋防污剂的应用
|
|
CN108658855A
(zh)
*
|
2017-03-28 |
2018-10-16 |
中国海洋大学 |
一种含氮双环化合物及其制备方法和用途
|
|
EP3606518A4
(en)
|
2017-04-01 |
2021-04-07 |
The Broad Institute, Inc. |
METHODS AND COMPOSITIONS FOR DETECTION AND MODULATION OF IMMUNOTHERAPY RESISTANCE GENE SIGNATURE IN CANCER
|
|
AR111960A1
(es)
|
2017-05-26 |
2019-09-04 |
Incyte Corp |
Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
|
|
JP7045726B2
(ja)
|
2017-06-16 |
2022-04-01 |
ベータ ファーマ，インコーポレイテッド |
Ｎ－（２－（２－（ジメチルアミノ）エトキシ）－４－メトキシ－５－（（４－（１－メチル－１ｈ－インドール－３－イル）ピリミジン－２－イル）アミノ）フェニル）アクリルアミドおよびその塩の医薬品製剤
|
|
MX392531B
(es)
|
2017-06-29 |
2025-03-24 |
G1 Therapeutics Inc |
Formas morficas de g1t38 y metodos de preparacion de las mismas.
|
|
EA036060B1
(ru)
*
|
2017-07-17 |
2020-09-21 |
Пфайзер Инк. |
Пиридопиримидиноновые ингибиторы cdk2/4/6
|
|
EA202090402A1
(ru)
|
2017-07-28 |
2020-05-19 |
Синтон Б.В. |
Фармацевтическая композиция, содержащая пальбоциклиб
|
|
CN109384767B
(zh)
*
|
2017-08-08 |
2020-05-05 |
江苏恒瑞医药股份有限公司 |
一种吡啶并嘧啶类衍生物的制备方法及其中间体
|
|
US20230160016A1
(en)
|
2017-08-31 |
2023-05-25 |
Novartis Ag |
Methods of selecting a treatment for cancer patients
|
|
CN107488175A
(zh)
*
|
2017-09-04 |
2017-12-19 |
上海微巨实业有限公司 |
一种帕博西林关键中间体的制备方法
|
|
EP3695408A4
(en)
|
2017-10-02 |
2021-12-15 |
The Broad Institute, Inc. |
METHODS AND COMPOSITIONS FOR DETECTING AND MODULATING A GENETIC SIGNATURE OF IMMUNOTHERAPY RESISTANCE IN CANCER
|
|
MX2020006587A
(es)
|
2017-12-22 |
2020-12-10 |
Ravenna Pharmaceuticals Inc |
Derivados de aminopiridina como inhibidores de fosfatidilinositol fosfato cinasa.
|
|
CN108586452A
(zh)
*
|
2018-01-12 |
2018-09-28 |
重庆市碚圣医药科技股份有限公司 |
一种帕博西尼中间体的合成方法
|
|
MX2020007959A
(es)
|
2018-01-29 |
2020-09-18 |
Beta Pharma Inc |
Derivados de 2h-indazol e inhibidores de cdk4 y cdk6 y sus usos terapeuticos.
|
|
CN108218861B
(zh)
*
|
2018-02-05 |
2019-07-23 |
黑龙江中医药大学 |
一种预防和治疗糖尿病的药物及其制备方法
|
|
EP3749654B1
(en)
|
2018-02-06 |
2025-04-23 |
The Board of Trustees of the University of Illinois |
Substituted benzothiophene analogs as selective estrogen receptor degraders
|
|
JP2021514975A
(ja)
|
2018-02-27 |
2021-06-17 |
ファイザー・インク |
サイクリン依存性キナーゼ阻害剤およびｂｅｔ−ブロモドメイン阻害剤の組合せ
|
|
CR20230030A
(es)
|
2018-02-27 |
2023-03-10 |
Incyte Corp |
Imidazopirimidinas y triazolopirimidinas como inhibidores de a2a / a2b (divisional 2020-0441)
|
|
BR112020022392A2
(pt)
|
2018-05-04 |
2021-02-02 |
Incyte Corporation |
formas sólidas de um inibidor de fgfr e processos para preparação das mesmas
|
|
PE20210919A1
(es)
|
2018-05-04 |
2021-05-19 |
Incyte Corp |
Sales de un inhibidor de fgfr
|
|
EP4309656A3
(en)
|
2018-05-14 |
2024-02-28 |
Pfizer Inc. |
Oral solution formulation
|
|
MX2020012376A
(es)
|
2018-05-18 |
2021-03-09 |
Incyte Corp |
Derivados de pirimidina fusionados como inhibidores de los receptores de adenosina a2a/a2b.
|
|
SI3802529T1
(sl)
|
2018-05-24 |
2024-03-29 |
Synthon B.V. |
Postopek za izdelavo palbocikliba
|
|
MX2021000116A
(es)
|
2018-07-05 |
2021-03-29 |
Incyte Corp |
Derivados de pirazina fusionados como inhibidores de a2a/a2b.
|
|
AU2019310335A1
(en)
|
2018-07-23 |
2021-02-11 |
F. Hoffmann-La Roche Ag |
Methods of treating cancer with PI3K inhibitor, GDC-0077
|
|
EP3830082B1
(en)
|
2018-07-27 |
2025-02-26 |
California Institute of Technology |
Cdk inhibitors and uses thereof
|
|
WO2020041770A1
(en)
|
2018-08-24 |
2020-02-27 |
G1 Therapeutics, Inc. |
Improved synthesis of 1,4-diazaspiro[5.5]undecan-3-one
|
|
JP6952747B2
(ja)
|
2018-09-18 |
2021-10-20 |
ファイザー・インク |
がん処置のためのＴＧＦβ阻害剤およびＣＤＫ阻害剤の組合せ
|
|
JP2022504388A
(ja)
|
2018-10-08 |
2022-01-13 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
Ｐｉ３ｋアルファ阻害剤およびメトホルミンを用いたがんの処置方法
|
|
US11066404B2
(en)
|
2018-10-11 |
2021-07-20 |
Incyte Corporation |
Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
|
|
US12358911B2
(en)
|
2018-12-07 |
2025-07-15 |
Hangzhou Innogate Pharma Co., Ltd. |
Heterocyclic comipound as CDK-HDAC dual pathway inhibitor
|
|
CN113195000A
(zh)
|
2018-12-21 |
2021-07-30 |
第一三共株式会社 |
抗体-药物缀合物和激酶抑制剂的组合
|
|
US20230065740A1
(en)
|
2018-12-28 |
2023-03-02 |
Spv Therapeutics Inc. |
Cyclin-dependent kinase inhibitors
|
|
US20230048132A1
(en)
*
|
2018-12-28 |
2023-02-16 |
Spv Therapeutics Inc. |
Cyclin-dependent kinase inhibitors
|
|
TWI829857B
(zh)
|
2019-01-29 |
2024-01-21 |
美商英塞特公司 |
作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶
|
|
WO2020157709A1
(en)
|
2019-02-01 |
2020-08-06 |
Pfizer Inc. |
Combination of a cdk inhibitor and a pim inhibitor
|
|
EP3923949A1
(en)
*
|
2019-02-15 |
2021-12-22 |
Incyte Corporation |
Cyclin-dependent kinase 2 biomarkers and uses thereof
|
|
WO2020168197A1
(en)
|
2019-02-15 |
2020-08-20 |
Incyte Corporation |
Pyrrolo[2,3-d]pyrimidinone compounds as cdk2 inhibitors
|
|
TW202100520A
(zh)
|
2019-03-05 |
2021-01-01 |
美商英塞特公司 |
作為cdk2 抑制劑之吡唑基嘧啶基胺化合物
|
|
US11628162B2
(en)
|
2019-03-08 |
2023-04-18 |
Incyte Corporation |
Methods of treating cancer with an FGFR inhibitor
|
|
US20220154282A1
(en)
|
2019-03-12 |
2022-05-19 |
The Broad Institute, Inc. |
Detection means, compositions and methods for modulating synovial sarcoma cells
|
|
WO2020205560A1
(en)
|
2019-03-29 |
2020-10-08 |
Incyte Corporation |
Sulfonylamide compounds as cdk2 inhibitors
|
|
US11440914B2
(en)
|
2019-05-01 |
2022-09-13 |
Incyte Corporation |
Tricyclic amine compounds as CDK2 inhibitors
|
|
WO2020223558A1
(en)
|
2019-05-01 |
2020-11-05 |
Incyte Corporation |
Tricyclic amine compounds as cdk2 inhibitors
|
|
JP2022534889A
(ja)
|
2019-05-24 |
2022-08-04 |
ファイザー・インコーポレイテッド |
Ｃｄｋ阻害剤を使用した組合せ療法
|
|
WO2020240360A1
(en)
|
2019-05-24 |
2020-12-03 |
Pfizer Inc. |
Combination therapies using cdk inhibitors
|
|
CN112010844B
(zh)
*
|
2019-05-31 |
2023-07-25 |
中国药科大学 |
N-(嘧啶-2-基)香豆素-7-胺衍生物作为蛋白激酶抑制剂的制法和应用
|
|
TW202112767A
(zh)
|
2019-06-17 |
2021-04-01 |
美商佩特拉製藥公司 |
作為磷脂酸肌醇磷酸激酶抑制劑之胺基吡啶衍生物
|
|
CN112094272A
(zh)
|
2019-06-18 |
2020-12-18 |
北京睿熙生物科技有限公司 |
Cdk激酶抑制剂
|
|
WO2020253808A1
(zh)
*
|
2019-06-20 |
2020-12-24 |
江苏恒瑞医药股份有限公司 |
一种药物组合物以及其制备方法
|
|
CN110143948B
(zh)
*
|
2019-06-21 |
2021-05-14 |
上海博悦生物科技有限公司 |
Cdk4/6抑制剂、其药物组合物、制备方法及应用
|
|
KR20220034129A
(ko)
|
2019-07-07 |
2022-03-17 |
올레마 파마슈티컬스 인코포레이티드 |
에스트로겐 수용체 길항제 요법
|
|
US11591329B2
(en)
|
2019-07-09 |
2023-02-28 |
Incyte Corporation |
Bicyclic heterocycles as FGFR inhibitors
|
|
JP2022543062A
(ja)
|
2019-08-01 |
2022-10-07 |
インサイト・コーポレイション |
Ｉｄｏ阻害剤の投与レジメン
|
|
TW202115024A
(zh)
|
2019-08-14 |
2021-04-16 |
美商英塞特公司 |
作為cdk2 抑制劑之咪唑基嘧啶基胺化合物
|
|
MX2022002415A
(es)
|
2019-08-26 |
2022-03-22 |
Arvinas Operations Inc |
Metodos de tratamiento del cancer de mama con derivados de tetrahidronaftaleno como degradadores del receptor de estrogenos.
|
|
US12122767B2
(en)
|
2019-10-01 |
2024-10-22 |
Incyte Corporation |
Bicyclic heterocycles as FGFR inhibitors
|
|
CN119930610A
(zh)
|
2019-10-11 |
2025-05-06 |
因赛特公司 |
作为cdk2抑制剂的双环胺
|
|
GEP20247679B
(en)
|
2019-10-14 |
2024-10-10 |
Incyte Corp |
Bicyclic heterocycles as fgfr inhibitors
|
|
WO2021076728A1
(en)
|
2019-10-16 |
2021-04-22 |
Incyte Corporation |
Bicyclic heterocycles as fgfr inhibitors
|
|
CN112759589B
(zh)
*
|
2019-11-01 |
2022-04-08 |
暨南大学 |
嘧啶并吡啶酮类化合物及其应用
|
|
US11697648B2
(en)
|
2019-11-26 |
2023-07-11 |
Theravance Biopharma R&D Ip, Llc |
Fused pyrimidine pyridinone compounds as JAK inhibitors
|
|
IL293347A
(en)
|
2019-12-03 |
2022-07-01 |
Genentech Inc |
Combination therapies for treatment of breast cancer
|
|
PE20221504A1
(es)
|
2019-12-04 |
2022-09-30 |
Incyte Corp |
Derivados de un inhibidor de fgfr
|
|
JP7720840B2
(ja)
|
2019-12-04 |
2025-08-08 |
インサイト・コーポレイション |
Ｆｇｆｒ阻害剤としての三環式複素環
|
|
IL293940A
(en)
|
2019-12-16 |
2022-08-01 |
Lunella Biotech Inc |
Selective cancer drugs cdk4/6 inhibitors
|
|
CN118652252A
(zh)
*
|
2019-12-16 |
2024-09-17 |
卢内拉生物技术有限公司 |
选择性cdk4/6抑制剂型癌症治疗药物
|
|
WO2021146424A1
(en)
|
2020-01-15 |
2021-07-22 |
Incyte Corporation |
Bicyclic heterocycles as fgfr inhibitors
|
|
TW202146017A
(zh)
|
2020-03-05 |
2021-12-16 |
美商輝瑞股份有限公司 |
間變性淋巴瘤激酶抑制劑及周期蛋白依賴型激酶抑制劑之組合
|
|
CN115697343A
(zh)
|
2020-03-06 |
2023-02-03 |
因赛特公司 |
包含axl/mer和pd-1/pd-l1抑制剂的组合疗法
|
|
JP7549032B2
(ja)
*
|
2020-03-13 |
2024-09-10 |
プロセネスター エルエルシー |
ＣＤＫ阻害剤としてのピリド［２，３－ｄ］ピリミジン－７（８Ｈ）－オン
|
|
JP2023518508A
(ja)
*
|
2020-03-27 |
2023-05-01 |
江蘇康寧杰瑞生物制薬有限公司 |
腫瘍を治療するための抗ｈｅｒ２抗体とｃｄｋ阻害剤の組み合わせ
|
|
JP2021167301A
(ja)
|
2020-04-08 |
2021-10-21 |
ファイザー・インク |
Ｃｄｋ２阻害剤に対する腫瘍適応を抑制するためのｃｄｋ４／６およびｃｄｋ２阻害剤による同時処置
|
|
BR112022020841A2
(pt)
|
2020-04-16 |
2023-05-02 |
Incyte Corp |
Inibidores de kras tricíclicos fundidos
|
|
WO2021231526A1
(en)
|
2020-05-13 |
2021-11-18 |
Incyte Corporation |
Fused pyrimidine compounds as kras inhibitors
|
|
MX2022014573A
(es)
|
2020-05-19 |
2022-12-15 |
G1 Therapeutics Inc |
Compuestos inhibidores de cinasa dependiente de ciclina para el tratamiento de trastornos medicos.
|
|
US20230132667A1
(en)
*
|
2020-05-28 |
2023-05-04 |
University Of Washington |
Drug-like molecules and methods for the therapeutic targeting of viral rna structures
|
|
US10988479B1
(en)
|
2020-06-15 |
2021-04-27 |
G1 Therapeutics, Inc. |
Morphic forms of trilaciclib and methods of manufacture thereof
|
|
CN113880809B
(zh)
|
2020-07-03 |
2022-10-18 |
盛世泰科生物医药技术(苏州)有限公司 |
一种嘧啶类衍生物及其制备方法和应用
|
|
PT4181920T
(pt)
|
2020-07-15 |
2025-11-04 |
Ctxt Pty Ltd |
Inibidor de kat6 e combinações para o tratamento do cancro da mama
|
|
CA3189632A1
(en)
|
2020-07-20 |
2022-01-27 |
Pfizer Inc. |
Combination therapy
|
|
US11999752B2
(en)
|
2020-08-28 |
2024-06-04 |
Incyte Corporation |
Vinyl imidazole compounds as inhibitors of KRAS
|
|
CN114246841B
(zh)
*
|
2020-09-24 |
2024-02-02 |
南京济群医药科技股份有限公司 |
一种羟乙磺酸哌柏西利的组合物及药物
|
|
CN114306245A
(zh)
|
2020-09-29 |
2022-04-12 |
深圳市药欣生物科技有限公司 |
无定形固体分散体的药物组合物及其制备方法
|
|
WO2022072783A1
(en)
|
2020-10-02 |
2022-04-07 |
Incyte Corporation |
Bicyclic dione compounds as inhibitors of kras
|
|
WO2022091001A1
(en)
|
2020-10-29 |
2022-05-05 |
Pfizer Ireland Pharmaceuticals |
Process for preparation of palbociclib
|
|
WO2022123419A1
(en)
|
2020-12-08 |
2022-06-16 |
Pfizer Inc. |
Treatment of luminal subtypes of hr-positive, her2-negative early breast cancer with palbociclib
|
|
CN112569361B
(zh)
*
|
2020-12-30 |
2023-01-10 |
扬子江药业集团上海海尼药业有限公司 |
一种哌柏西利干混悬组合物及其制备方法
|
|
WO2022155941A1
(en)
|
2021-01-25 |
2022-07-28 |
Qilu Regor Therapeutics Inc. |
Cdk2 inhibitors
|
|
WO2022162122A1
(en)
|
2021-01-29 |
2022-08-04 |
Biotx.Ai Gmbh |
Genetically verified netosis inhibitor for use in the treatment of a sars-cov2 infection
|
|
WO2022206888A1
(en)
|
2021-03-31 |
2022-10-06 |
Qilu Regor Therapeutics Inc. |
Cdk2 inhibitors and use thereof
|
|
TW202304459A
(zh)
|
2021-04-12 |
2023-02-01 |
美商英塞特公司 |
包含ｆｇｆｒ抑制劑及ｎｅｃｔｉｎ－４靶向劑之組合療法
|
|
TWI823420B
(zh)
*
|
2021-06-09 |
2023-11-21 |
大陸商鄭州同源康醫藥有限公司 |
用作cdk激酶抑制劑的化合物及其應用
|
|
CA3220155A1
(en)
|
2021-06-09 |
2022-12-15 |
Incyte Corporation |
Tricyclic heterocycles as fgfr inhibitors
|
|
TW202313611A
(zh)
|
2021-06-09 |
2023-04-01 |
美商英塞特公司 |
作為ｆｇｆｒ抑制劑之三環雜環
|
|
US11981671B2
(en)
|
2021-06-21 |
2024-05-14 |
Incyte Corporation |
Bicyclic pyrazolyl amines as CDK2 inhibitors
|
|
AU2022306671A1
(en)
|
2021-07-07 |
2024-01-25 |
Incyte Corporation |
Tricyclic compounds as inhibitors of kras
|
|
US20230114765A1
(en)
|
2021-07-14 |
2023-04-13 |
Incyte Corporation |
Tricyclic compounds as inhibitors of kras
|
|
JP2024529430A
(ja)
|
2021-07-26 |
2024-08-06 |
セルキュイティー インコーポレイテッド |
がんの処置における使用のための１－（４－｛［４－（ジメチルアミノ）ピペリジン－１－イル］カルボニル｝フェニル）－３－［４－（４，６－ジモルホリン－４－イル－１，３，５－トリアジン－２－イル）フェニル］尿素（ゲダトリシブ）およびその組合せ
|
|
JP2024534187A
(ja)
|
2021-08-31 |
2024-09-18 |
インサイト・コーポレイション |
Ｋｒａｓの阻害剤としてのナフチリジン化合物
|
|
CN113683612B
(zh)
*
|
2021-09-07 |
2022-06-17 |
山东铂源药业股份有限公司 |
一种帕布昔利布的制备方法
|
|
CN118119393A
(zh)
*
|
2021-09-14 |
2024-05-31 |
甘李药业股份有限公司 |
一种cdk4/6抑制剂的医药用途
|
|
US12030883B2
(en)
|
2021-09-21 |
2024-07-09 |
Incyte Corporation |
Hetero-tricyclic compounds as inhibitors of KRAS
|
|
CA3234375A1
(en)
|
2021-10-01 |
2023-04-06 |
Incyte Corporation |
Pyrazoloquinoline kras inhibitors
|
|
PE20242113A1
(es)
|
2021-10-14 |
2024-10-28 |
Incyte Corp |
Compuestos de quinolina como inhibidores de kras
|
|
IL312886A
(en)
|
2021-11-22 |
2024-07-01 |
Incyte Corp |
Combined treatment that includes a Pegfer inhibitor and a Kras inhibitor
|
|
WO2023102184A1
(en)
|
2021-12-03 |
2023-06-08 |
Incyte Corporation |
Bicyclic amine compounds as cdk12 inhibitors
|
|
WO2023107525A1
(en)
|
2021-12-10 |
2023-06-15 |
Eli Lilly And Company |
Cdk4 and 6 inhibitor in combination with fulvestrant for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced or metastatic breast cancer in patients previously treated with a cdk4 and 6 inhibitor
|
|
WO2023107705A1
(en)
|
2021-12-10 |
2023-06-15 |
Incyte Corporation |
Bicyclic amines as cdk12 inhibitors
|
|
US11976073B2
(en)
|
2021-12-10 |
2024-05-07 |
Incyte Corporation |
Bicyclic amines as CDK2 inhibitors
|
|
WO2023111810A1
(en)
|
2021-12-14 |
2023-06-22 |
Pfizer Inc. |
Combination therapies and uses for treating cancer
|
|
WO2023114264A1
(en)
|
2021-12-15 |
2023-06-22 |
Eli Lilly And Company |
Combination for treatment of high-risk metastatic hormone-sensitive prostate cancer
|
|
IL313735A
(en)
|
2021-12-22 |
2024-08-01 |
Incyte Corp |
Salts and solid forms of Pajfer inhibitor and processes for their preparation
|
|
WO2023116884A1
(en)
|
2021-12-24 |
2023-06-29 |
Qilu Regor Therapeutics Inc. |
Cdk2 inhibitors and use thereof
|
|
WO2023168686A1
(en)
|
2022-03-11 |
2023-09-14 |
Qilu Regor Therapeutics Inc. |
Substituted cyclopentanes as cdk2 inhibitors
|
|
CN114456180B
(zh)
*
|
2022-02-18 |
2023-07-25 |
贵州大学 |
用于治疗和/或预防恶性肿瘤的化合物及药物制剂和应用
|
|
MX2024010863A
(es)
|
2022-03-07 |
2024-09-11 |
Incyte Corp |
Formas solidas, sales y procesos de preparacion de un inhibidor de cinasas dependientes de ciclina 2 (cdk2).
|
|
HU231594B1
(hu)
*
|
2022-05-10 |
2025-03-28 |
Egis Gyógyszergyár Zrt. |
Palbociclibet és letrozolt tartalmazó gyógyszerkészítmény
|
|
WO2023250430A1
(en)
|
2022-06-22 |
2023-12-28 |
Incyte Corporation |
Bicyclic amine cdk12 inhibitors
|
|
EP4302755B1
(en)
|
2022-07-07 |
2025-08-20 |
Lotus Pharmaceutical Co., Ltd. |
Palbociclib formulation containing an amino acid
|
|
EP4302832A1
(en)
|
2022-07-07 |
2024-01-10 |
Lotus Pharmaceutical Co., Ltd. |
Palbociclib formulation containing glucono delta lactone
|
|
WO2024015731A1
(en)
|
2022-07-11 |
2024-01-18 |
Incyte Corporation |
Fused tricyclic compounds as inhibitors of kras g12v mutants
|
|
CN117430597A
(zh)
*
|
2022-07-14 |
2024-01-23 |
浙江同源康医药股份有限公司 |
用作cdk4激酶抑制剂的化合物及其应用
|
|
JP2025533719A
(ja)
|
2022-07-29 |
2025-10-09 |
ファイザー・インク |
がんの治療のためのｋａｔ６阻害剤を含む投与レジメン
|
|
TWI866427B
(zh)
|
2022-08-31 |
2024-12-11 |
美商亞文納營運公司 |
雌激素受體降解劑之給藥方案
|
|
CN120456897A
(zh)
|
2022-11-02 |
2025-08-08 |
佩特拉制药公司 |
用于治疗疾病的磷酸肌醇3-激酶(pi3k)变构色原酮抑制剂
|
|
WO2024100236A1
(en)
|
2022-11-11 |
2024-05-16 |
Astrazeneca Ab |
Combination therapies for the treatment of cancer
|
|
WO2024125581A2
(zh)
*
|
2022-12-16 |
2024-06-20 |
上海岸阔医药科技有限公司 |
化合物及其用途
|
|
WO2024133726A1
(en)
|
2022-12-22 |
2024-06-27 |
Synthon B.V. |
Pharmaceutical composition comprising palbociclib
|
|
WO2024132652A1
(en)
|
2022-12-22 |
2024-06-27 |
Synthon B.V. |
Pharmaceutical composition comprising palbociclib
|
|
KR20250164842A
(ko)
|
2023-03-30 |
2025-11-25 |
화이자 인코포레이티드 |
Kat6a 억제제에 의한 치료를 위한 예측 바이오마커로서의 kat6a 및 이의 치료 방법
|
|
WO2024201340A1
(en)
|
2023-03-30 |
2024-10-03 |
Pfizer Inc. |
Kat6a as a predictive biomarker for treatment of breast cancer with a cdk4 inhibitor and an antiestrogen and methods of treatment thereof
|
|
US20240390340A1
(en)
|
2023-04-18 |
2024-11-28 |
Incyte Corporation |
Pyrrolidine kras inhibitors
|
|
WO2024220645A1
(en)
|
2023-04-18 |
2024-10-24 |
Incyte Corporation |
2-azabicyclo[2.2.1]heptane kras inhibitors
|
|
TW202508598A
(zh)
|
2023-05-05 |
2025-03-01 |
瑞典商阿斯特捷利康公司 |
癌症療法
|
|
WO2024235844A1
(en)
|
2023-05-12 |
2024-11-21 |
Institut National de la Santé et de la Recherche Médicale |
Methods of preventing on-target genotoxicity induced by nucleases
|
|
WO2024254245A1
(en)
|
2023-06-09 |
2024-12-12 |
Incyte Corporation |
Bicyclic amines as cdk2 inhibitors
|
|
WO2025051337A1
(en)
|
2023-09-06 |
2025-03-13 |
Afyx Development A/S |
Compositions and methods for treating and preventing oral cancer
|
|
WO2025096738A1
(en)
|
2023-11-01 |
2025-05-08 |
Incyte Corporation |
Kras inhibitors
|
|
TW202532065A
(zh)
|
2023-12-04 |
2025-08-16 |
美商建南德克公司 |
治療乳癌之組合療法
|
|
WO2025129002A1
(en)
|
2023-12-13 |
2025-06-19 |
Incyte Corporation |
Bicyclooctane kras inhibitors
|
|
WO2025202854A1
(en)
|
2024-03-27 |
2025-10-02 |
Pfizer Inc. |
Cdk4 inhibitors and combinations with cdk2 inhibitors or further agents for use in the treatment of cancer
|